VTRS vs ZTS vs ELAN
161 measures in 16 categories, one definition each, computed from filings and market data.
VTRS37.1
Viatris Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$18.66 +2.41%$21.4B mkt cap
Score DNA
ZTS66.0
Zoetis Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$79.32 +1.20%$32.8B mkt cap
Score DNA
ELAN26.5
Elanco Animal Health Incorporated
Healthcare · Drug Manufacturers - Specialty & Generic
$23.55 +0.08%$11.8B mkt cap
Score DNA
Price, rebased to 100 three years ago
VTRS ZTS ELAN · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 3 | 7 |
| Insider $ bought, 180d | — | $0.89M | $1.67M |
| Congress purchases, 180d | 0 | 16 | 0 |
| Last Congress purchase | — | 2026-09-18 | — |
| 13F net change in holders | +8 | — | +6 |
| ETFs adding shares, 30d | 637 | 1,343 | 348 |
| ETFs trimming, 30d | 594 | 1,138 | 210 |
| Net ETF funds, 30d | +43 | +205 | +138 |
Valuation
16 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| P/E (TTM) | — | 12.5x
20th
|
— |
| PEG (P/E ÷ 3-yr EPS CAGR) | — | 1.33 | — |
| Price / sales | 1.5x
21st
|
3.4x
64th
|
2.3x
50th
|
| Price / book | 1.5x
24th
|
10.4x
86th
|
1.8x
33rd
|
| Price / tangible book | — | — | — |
| Price / free cash flow | 11.4x
35th
|
13.9x
45th
|
31.0x
65th
|
| Price / operating cash flow | 9.2x
40th
|
11.4x
45th
|
19.1x
60th
|
| Enterprise value | $33.5B
93rd
|
$40.3B
96th
|
$15.2B
86th
|
| EV / sales | 2.3x
50th
|
4.2x
75th
|
3.0x
61st
|
| EV / EBITDA | 12.3x
50th
|
10.1x
39th
|
19.6x
72nd
|
| EV / EBIT | — | 11.5x
27th
|
187.0x
100th
|
| EV / free cash flow | 17.9x
55th
|
17.0x
50th
|
40.0x
70th
|
| Earnings yield | -1.9%
39th
|
8.0%
89th
|
-1.7%
43rd
|
| FCF yield | 8.7%
75th
|
7.2%
68th
|
3.2%
54th
|
| Operating cash flow yield | 10.9%
71st
|
8.8%
68th
|
5.2%
57th
|
| Graham number (per share) | — | $32.59
85th
|
— |
Profitability (TTM)
12 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Gross margin | 34.8%
18th
|
70.9%
75th
|
52.6%
43rd
|
| EBITDA margin | 18.4%
61st
|
42.0%
93rd
|
15.4%
54th
|
| Operating margin | -0.6%
21st
|
37.0%
96th
|
9.2%
46th
|
| EBIT margin | -0.6%
39th
|
36.9%
96th
|
1.6%
46th
|
| Net margin | -2.8%
43rd
|
27.5%
89th
|
-4.0%
39th
|
| NOPAT margin | -0.5%
21st
|
29.6%
93rd
|
7.3%
46th
|
| FCF margin | 12.7%
57th
|
24.9%
89th
|
7.5%
46th
|
| Operating cash flow margin | 15.8%
64th
|
30.3%
93rd
|
12.3%
50th
|
| R&D / revenue | 6.9%
54th
|
7.6%
64th
|
7.4%
57th
|
| SG&A / revenue | 27.0%
43rd
|
25.0%
39th
|
30.3%
57th
|
| Stock comp / revenue | 1.2%
23rd
|
1.0%
19th
|
1.5%
38th
|
| Effective tax rate | 21.0%
32nd
|
20.0%
29th
|
21.0%
32nd
|
Returns on capital
11 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| ROE (on average equity) | -2.8%
35th
|
64.4%
100th
|
-3.0%
30th
|
| ROA | -1.1%
43rd
|
17.7%
89th
|
-1.5%
39th
|
| ROIC | -0.3%
18th
|
26.3%
86th
|
3.7%
43rd
|
| ROCE | -0.3%
36th
|
27.0%
93rd
|
0.7%
46th
|
| Return on tangible assets | -0.2%
39th
|
23.8%
93rd
|
0.6%
46th
|
| Cash ROIC (OCF / invested capital) | 8.8%
46th
|
27.0%
81st
|
6.2%
35th
|
| Gross profitability (GP / assets) | 14.6%
11th
|
44.7%
75th
|
19.5%
29th
|
| ROIC, 3-yr average | -3.7%
30th
|
21.5%
91st
|
-0.6%
43rd
|
| ROIC, 5-yr average | -1.6%
26th
|
23.2%
84th
|
-1.1%
32nd
|
| ROE, 5-yr average | -3.1%
50th
|
55.3%
100th
|
-4.3%
40th
|
| Incremental ROIC | -109.4%
11th
|
117.6%
86th
|
-4.6%
50th
|
Growth
17 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Revenue growth (TTM YoY) | 4.4%
36th
|
1.4%
25th
|
12.0%
54th
|
| Revenue growth (QoQ) | 6.8%
46th
|
9.1%
61st
|
-0.2%
7th
|
| Revenue CAGR, 3 yr | -1.9%
11th
|
5.0%
36th
|
5.1%
39th
|
| Revenue CAGR, 5 yr | -1.1%
8th
|
5.1%
24th
|
2.0%
20th
|
| Gross profit CAGR, 3 yr | -6.0%
0th
|
6.3%
20th
|
10.6%
48th
|
| Operating income CAGR, 3 yr | — | 5.8%
23rd
|
9.6%
38th
|
| Net income growth (TTM YoY) | — | 0.2%
20th
|
— |
| Net income CAGR, 3 yr | — | 5.7%
40th
|
— |
| EPS growth (TTM YoY) | — | 6.8%
30th
|
— |
| EPS CAGR, 3 yr | — | 9.4%
40th
|
— |
| EPS CAGR, 5 yr | — | 9.4%
57th
|
— |
| FCF growth (TTM YoY) | 10.5%
61st
|
6.6%
44th
|
6.8%
50th
|
| FCF CAGR, 3 yr | -2.9%
29th
|
22.6%
79th
|
— |
| Operating cash flow CAGR, 3 yr | -2.4%
19th
|
13.0%
62nd
|
73.6%
100th
|
| Book value CAGR, 3 yr | -10.9%
33rd
|
-9.0%
38th
|
-4.7%
43rd
|
| Dividend CAGR, 3 yr | 0.4%
60th
|
5.5%
80th
|
— |
| Sustainable growth rate | — | 42.5%
92nd
|
— |
Margin history & stability
7 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Gross margin, 3-yr average | 37.5%
21st
|
69.7%
75th
|
46.2%
36th
|
| Operating margin, 3-yr average | -6.4%
29th
|
36.9%
96th
|
6.8%
54th
|
| Net margin, 3-yr average | -10.5%
32nd
|
27.2%
96th
|
-7.4%
36th
|
| FCF margin, 3-yr average | 12.4%
64th
|
24.0%
89th
|
8.3%
46th
|
| Revenue stability (0-1) | 0.59
21st
|
0.97
89th
|
0.31
11th
|
| Earnings stability (0-1) | 0.04
14th
|
0.97
100th
|
0.09
32nd
|
| Margin stability (0-1) | 0.86
29th
|
0.98
86th
|
0.90
36th
|
Liquidity (latest quarter)
7 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Cash & short-term investments | $1.5B
89th
|
$1.7B
93rd
|
$530.0M
71st
|
| Net cash (− = net debt) | −$12.1B
7th
|
−$7.6B
11th
|
−$3.4B
14th
|
| Working capital | $3.7B
96th
|
$4.3B
100th
|
$1.9B
89th
|
| Current ratio | 1.58
18th
|
3.08
71st
|
2.05
36th
|
| Quick ratio | 0.96
18th
|
1.84
54th
|
1.10
25th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.24
11th
|
0.81
50th
|
0.29
21st
|
| Defensive interval (days) | 362 days
32nd
|
368 days
43rd
|
282 days
18th
|
Leverage & solvency (latest quarter)
13 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Total debt | $13.6B
93rd
|
$9.2B
89th
|
$3.9B
86th
|
| Debt / equity | 0.96
62nd
|
2.93
90th
|
0.59
38th
|
| Net debt / equity | 0.85
62nd
|
2.40
90th
|
0.51
52nd
|
| Debt / assets | 38.9%
43rd
|
61.3%
75th
|
28.9%
32nd
|
| Debt / capital | 48.9%
62nd
|
74.6%
90th
|
37.3%
38th
|
| Debt / EBITDA | 5.02
67th
|
2.31
39th
|
5.06
72nd
|
| Net debt / EBITDA | 4.46
83rd
|
1.89
50th
|
4.38
78th
|
| Interest coverage (EBIT / interest) | −0.2x
38th
|
14.4x
88th
|
0.3x
42nd
|
| Cash interest coverage | 4.9x
65th
|
11.8x
88th
|
2.4x
58th
|
| Debt payback (years of OCF) | 5.8 yrs
55th
|
3.2 yrs
45th
|
6.4 yrs
70th
|
| Liabilities / assets | 59.3%
39th
|
79.1%
61st
|
51.4%
29th
|
| IS credit model rating | B | AA | B+ |
| Implied credit spread (bps) | 750
64th
|
80
11th
|
650
57th
|
Efficiency
11 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Asset turnover | 0.40
21st
|
0.64
68th
|
0.37
11th
|
| Fixed asset turnover | 5.46
54th
|
2.36
18th
|
3.56
21st
|
| Inventory turnover | 2.3
56th
|
1.1
15th
|
1.4
26th
|
| Receivables turnover | 5.5
61st
|
6.1
89th
|
4.9
39th
|
| Days sales outstanding | 67 days
39th
|
60 days
11th
|
75 days
61st
|
| Days inventory outstanding | 156 days
44th
|
330 days
85th
|
264 days
74th
|
| Days payables outstanding | 49 days
29th
|
63 days
50th
|
61 days
43rd
|
| Cash conversion cycle (days) | 174 days
46th
|
326 days
96th
|
278 days
89th
|
| Capex / revenue | 3.1%
54th
|
5.5%
93rd
|
4.7%
82nd
|
| Capex / depreciation | 0.16
25th
|
1.08
75th
|
0.34
39th
|
| Operating expense ratio | 38.6%
36th
|
34.8%
29th
|
50.4%
61st
|
Cash flow & earnings quality
7 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Operating cash flow / net income | — | 1.10
27th
|
— |
| FCF / net income | — | 0.90
33rd
|
— |
| FCF / operating cash flow | 80.4%
35th
|
82.0%
40th
|
61.4%
10th
|
| Capex / operating cash flow | 19.6%
65th
|
18.0%
60th
|
38.6%
90th
|
| Accruals ratio | -7.5%
39th
|
-1.8%
75th
|
-6.0%
50th
|
| Sloan accruals ratio | -4.7%
46th
|
8.5%
82nd
|
-7.1%
36th
|
| Earnings quality score (0-1) | — | 1.00
73rd
|
— |
Scores & forensic checks
15 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| IS score | 37
36th
|
66
82nd
|
26
21st
|
| IS profitability | 12
4th
|
98
100th
|
25
39th
|
| IS growth | 71
68th
|
47
32nd
|
42
25th
|
| IS value | 49
64th
|
71
89th
|
39
39th
|
| IS momentum | 68
54th
|
66
50th
|
42
21st
|
| IS risk (safety) | 15
25th
|
100
86th
|
30
43rd
|
| IS quality | 48
39th
|
68
71st
|
51
50th
|
| IS balance sheet | 36
36th
|
56
64th
|
42
50th
|
| IS earnings quality | 43
32nd
|
76
100th
|
48
43rd
|
| IS cash flow | 49
54th
|
65
68th
|
41
50th
|
| Piotroski F-score (0-9) | 7
68th
|
6
54th
|
5
29th
|
| Altman Z-score | 1.1
36th
|
4.6
86th
|
1.4
43rd
|
| Beneish M-score | −2.93
21st
|
−2.55
61st
|
−2.85
36th
|
| Ohlson O-score | −8.03
21st
|
−7.32
36th
|
−7.49
32nd
|
| IS credit score | 26
29th
|
85
89th
|
35
43rd
|
Size (TTM)
8 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| Market cap | $21.4B
93rd
|
$32.8B
96th
|
$11.8B
89th
|
| Revenue | $14.7B
96th
|
$9.5B
89th
|
$5.0B
86th
|
| EBITDA | $2.7B
96th
|
$4.0B
100th
|
$774.0M
86th
|
| Net income | −$410.7M
7th
|
$2.6B
100th
|
−$199.0M
11th
|
| Free cash flow | $1.9B
96th
|
$2.4B
100th
|
$379.0M
82nd
|
| Total assets | $35.0B
96th
|
$15.1B
89th
|
$13.6B
86th
|
| Shareholders' equity | $14.3B
100th
|
$3.1B
89th
|
$6.6B
93rd
|
| Employees | 30,000
96th
|
14,500
89th
|
9,650
86th
|
Price performance
9 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| 1 day | +2.4% | +1.2% | +0.1% |
| 1 week | +5.8% | +6.1% | +2.8% |
| 1 month | +8.9% | +8.7% | +3.6% |
| 3 months | +9.8% | +4.2% | −6.3% |
| 6 months | +27.1% | −34.9% | −0.5% |
| Year to date | +49.8% | −36.7% | +4.6% |
| 1 year | +89.1% | −44.0% | +14.9% |
| 3 years, cumulative | +113.5% | −54.0% | +138.5% |
| 5 years, cumulative | +65.1% | −58.2% | −28.9% |
Technicals
4 measures| Measure | VTRS | ZTS | ELAN |
|---|---|---|---|
| RSI 14 | 69.2 | 69.4 | 58.5 |
| From 52-week high | −0.1% | −46.3% | −15.8% |
| From 52-week low | +90.4% | +15.4% | +21.4% |
| Beta | 0.86 | 0.74 | 1.71 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17